{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:54:44Z","timestamp":1790686484584,"version":"4.1.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100005933","name":"Camurus Lipid Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Opioid agonist treatment (OAT) is the mainstay for opioid use disorder (OUD). Long-acting injectable buprenorphine may address limitations of daily medications by reducing treatment burden and improving engagement. This study assessed retention and patient-reported outcomes with Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in France.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This multicenter, observational, retrospective study analyzed medical records of adults diagnosed with OUD who received \u22651 Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injection between July 2021 and August 2023. The primary endpoint was retention at 6\u2009months. Key secondary endpoints included changes in opioid consumption, perceived improvement in OUD using the Patient Global Impression of Change (PGIC) scale, distancing from OUD, reduction in craving, and satisfaction with Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 101 participants (mean age 43.9\u2009years; 72.3% male; 98.0% switched to Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      from previous OAT), 74 (73.3%) were retained on Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      at 6\u2009months. Of those using non-prescribed or misused opioids at baseline, decreased consumption of non-prescribed or misused opioids during treatment with Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      was reported by 80.0% (16\/20) of retained participants and 66.7% (8\/12) of non-retained participants. A significantly higher proportion of retained than non-retained participants reported improvement in OUD on PGIC (85.1% [63\/74] vs 40.7% [11\/27];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), increased distancing from OUD (90.5% [67\/74] vs 70.4% [19\/27];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.02), and reduced craving (91.9% [68\/74] vs 66.7% [18\/27];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Satisfaction with Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      was high overall (89.1% [90\/101]), with 98.6% (73\/74) of retained participants satisfied compared with 63.0% (17\/27) of non-retained participants (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Among retained participants, 91.9% (68\/74) expressed willingness to continue Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      treatment beyond 6\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Nearly three-quarters of participants initiating Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      were retained in treatment at 6\u2009months. Patient-reported outcomes indicated high satisfaction, perceived improvement in OUD, and reductions in opioid consumption and craving, even among individuals largely stabilized on OAT at baseline. These findings suggest that Buvidal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      may support sustained engagement and meaningful improvements in patient experience under real-world conditions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342261433342","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:59:00Z","timestamp":1778763540000},"page":"1012-1026","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal\n                    <sup>\u00ae<\/sup>\n                    ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)"],"prefix":"10.1177","volume":"47","author":[{"given":"Alice","family":"Deschenau","sequence":"first","affiliation":[{"name":"Service Addictions, GH Paul-Guiraud, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Melin","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine et d\u2019Addictologie, Centre Hospitalier Genevi\u00e8ve\u2011de\u2011Gaulle\u2011Anthonioz, Saint\u2011Dizier, France"},{"name":"Centre de Soins, d\u2019Accompagnement et de Pr\u00e9vention en Addictologie (CSAPA 52), Saint\u2013Dizier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Azuar","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique, Site Lariboisi\u00e8re Fernand-Widal, GHU AP-HP Nord-Universit\u00e9 Paris Cit\u00e9, AP-HP, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Touchon","sequence":"additional","affiliation":[{"name":"Camurus SAS, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vinel-Jacquet","sequence":"additional","affiliation":[{"name":"Service d\u2019Addictologie et de Psychiatrie, AP-HM, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Trojak","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire d\u2019Addictologie, CHU Dijon Bourgogne, France"},{"name":"INSERM U1093, UFR STAPS, Universit\u00e9 de Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Blecha","sequence":"additional","affiliation":[{"name":"H\u00f4pital Paul-Brousse, Assistance Publique-H\u00f4pitaux de Paris, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Cab\u00e9","sequence":"additional","affiliation":[{"name":"Service d\u2019Addictologie et Pathologies Duelles, CHU de Clermont-Ferrand, France"},{"name":"Clermont Auvergne INP, CHU Clermont-Ferrand, CNRS, Institut Pascal, Universit\u00e9 Clermont Auvergne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Kosim","sequence":"additional","affiliation":[{"name":"Camurus SAS, Paris, France"},{"name":"Consultations de M\u00e9decine-Alcoologie PASS, Assistance Publique-H\u00f4pitaux de Paris, GHU Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Dupeyron","sequence":"additional","affiliation":[{"name":"Pole Addiction et Pr\u00e9carit\u00e9, Centre Hospitalier Guillaume R\u00e9gnier, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Daulou\u00e8de","sequence":"additional","affiliation":[{"name":"CNRS, SANPSY, UMR 6033, Bordeaux, France"},{"name":"Centre de Soins et d\u2019Accompagnement et de Pr\u00e9vention en Addictologie (CSAPA), BIZIA, M\u00e9decins du Monde, Centre Hospitalier de la C\u00f4te Basque, Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Brousse","sequence":"additional","affiliation":[{"name":"Service Psychiatrie et Addictologie de l\u2019Adulte CMP B, Centre Hospitalier Universitaire (CHU), Clermont-Ferrand, France"},{"name":"Clermont Auvergne INP, CHU Clermont-Ferrand, CNRS, Institut Pascal, Universit\u00e9 Clermont Auvergne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Chappuy","sequence":"additional","affiliation":[{"name":"Service Universitaire d\u2019Addictologie de Lyon (SUAL), H\u00f4pital Edouard Herriot, Hospices Civils de Lyon, France"},{"name":"CSAPA, H\u00f4pital de la Croix Rousse, Hospices Civils de Lyon, France"},{"name":"Service Pharmaceutique, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-3635","authenticated-orcid":false,"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[{"name":"Service Universitaire d\u2019Addictologie de Lyon (SUAL), Hospices Civils de Lyon, France"},{"name":"Service Universitaire d\u2019Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France"},{"name":"CRNL, UMR 5292 CNRS\/1028 INSERM \u2013 Universit\u00e9 Lyon 1, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"StatPearls","author":"Dydyk AM","year":"2025","unstructured":"Dydyk AM, Jain NK, Gupta M. Opioid use disorder: evaluation and management. In: StatPearls (Internet). StatPearls Publishing LLC; 2025."},{"key":"e_1_3_3_3_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report \u2013 trends and developments. 2017. Accessed April 30 2025. https:\/\/www.euda.europa.eu\/publications\/edr\/trends-developments\/2017_en"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/ceor.S85213"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.020"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15580"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.91934"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108492"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1649252"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2024.09.003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000045"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000001484"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102311"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/10398562241295872"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175575"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00474-2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i9.543"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.05.007"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15627"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2024.2369756"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52250"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.62401\/2531-4122-2024-9"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.541"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-025-00967-y"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104390"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100128"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-023-01348-5"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-13607-7"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209348"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108661"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.70105"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2147\/sar.S266838"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2018.03.056"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1379412"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6657350"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32259-1"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2019.1706552"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100233"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32229-9"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/ceor.S256714"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103978"},{"key":"e_1_3_3_46_2","unstructured":"European Medicines Agency (EMA). Buvidal\u00ae summary of product characteristics. 2018. Accessed December 1 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/buvidal-epar-product-information_en.pdf"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261433342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261433342","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261433342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:57:12Z","timestamp":1790683032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261433342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/29767342261433342"],"URL":"https:\/\/doi.org\/10.1177\/29767342261433342","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}